Brensocatib monohydrate at a glance
Medicine class
DPP1 inhibitor
Licensed use
Non-cystic fibrosis bronchiectasis with recurrent exacerbations in people aged 12 years and over
Administration
Film-coated tablet taken by mouth, with or without food
Safety status
Subject to additional monitoring; suspected adverse reactions should be reported
What is Brensocatib monohydrate used for?
Licensed use:
Non-cystic fibrosis bronchiectasis in people aged 12 years and over who experienced at least two exacerbations during the previous 12 months.
How does Brensocatib monohydrate work?
Brensocatib blocks DPP1, an enzyme that activates inflammatory neutrophil serine proteases. This reduces the activity of enzymes that contribute to airway inflammation and damage in bronchiectasis.
Brensocatib monohydrate preparations and strengths
Tablet
Route: Oral
Strengths: 25 mg
How to take Brensocatib monohydrate
Take the film-coated tablet by mouth exactly as prescribed. It may be taken with or without food.
Keep tablets in their original packaging to protect them from moisture.
Do not stop treatment without discussing it with the prescriber.
Brensocatib monohydrate side effects
Common or expected effects
- Upper respiratory tract infection
- Gastroenteritis
- Headache
- Gum disorders
- Periodontal disease
- Areas of thickened skin
- Rash
- Dry skin or dermatitis
- Skin peeling
- Hair loss
Brensocatib monohydrate in pregnancy
There are no human pregnancy data, and the potential benefits and risks have not been established. Use requires an individual prescriber assessment of expected maternal benefit against unknown fetal risk.
Brensocatib monohydrate while breastfeeding
It is unknown whether brensocatib enters human milk or affects a breastfed child. The benefit of breastfeeding should be weighed against the benefit of treatment when deciding whether to pause breastfeeding or brensocatib.
Brensocatib monohydrate interactions
Tell the prescriber or pharmacist about all medicines and planned vaccinations. Interaction studies were conducted only in adults.
Live attenuated vaccines
Concurrent use has not been evaluated and should be avoided during treatment.
CYP3A4-substrate inhaled corticosteroids
Brensocatib may reduce their concentrations and therapeutic effect; review inhaled treatment if effectiveness declines.
CYP3A4-substrate macrolide antibiotics
Their concentrations and therapeutic effect may be reduced; assess concurrent treatment if effectiveness declines.
Common questions about Brensocatib monohydrate
Answers are fully visible for fast scanning and source review.
Is brensocatib an antibiotic?
No. It is a DPP1 inhibitor that targets inflammatory neutrophil-protease activity rather than directly killing bacteria.
Can children take brensocatib?
It is licensed from age 12. Safety and efficacy have not been established in younger children.
Can I have vaccines while taking brensocatib?
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.